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Background: Acute respiratory distress syndrome (ARDS) is a potentially devastating refractory hypoxemic illness
with multi-organ involvement. Although several randomised controlled trials into ventilator and fluid management
strategies have provided level 1 evidence to guide supportive therapy, there are few, established guidelines on
how to manage patients with ARDS. In addition, and despite their continued use, pharmacotherapies for ARDS
disease modulation have no proven benefit in improving mortality. Little is known however about the variability in
diagnostic and treatment practices across the United Kingdom (UK). The aim of this survey, therefore, was to assess
the use of diagnostic criteria and treatment strategies for ARDS in critical care units across the UK.
Methods: The survey questionnaire was developed and internally piloted at University Hospital Southampton
NHS Foundation Trust. Following ethical approval from University of Southampton Ethics and Research Committee,
a link to an online survey engine (Survey Monkey) was then placed on the Intensive Care Society (UK) website.
Fellows of The Intensive Care Society were subsequently personally approached via e-mail to encourage
participation. The survey was conducted over a period of 3 months.
Results: The survey received 191 responses from 125 critical care units, accounting for 11% of all registered
intensive care physicians at The Intensive Care Society. The majority of the responses were from physicians
managing general intensive care units (82%) and 34% of respondents preferred the American European Consensus
Criteria for ARDS. There was a perceived decline in both incidence and mortality in ARDS. Primary ventilation
strategies were based on ARDSnet protocols, though frequent deviations from ARDSnet positive end expiratory
pressure (PEEP) recommendations (51%) were described. The majority of respondents set permissive blood gas
targets (hypoxia (92%), hypercapnia (58%) and pH (90%)). The routine use of pharmacological agents is rare.
Neuromuscular blockers and corticosteroids are considered occasionally and on a case-by-case basis. Routine (58%)
or late (64%) tracheostomy was preferred to early tracheostomy insertion. Few centres offered routine follow-up or
dedicated rehabilitation programmes following hospital discharge.
Conclusions: There is substantial variation in the diagnostic and management strategies employed for patients
with ARDS across the UK. National and/or international guidelines may help to improve standardisation in the
management of ARDS.
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Acute respiratory distress syndrome (ARDS) is a severe
form of hypoxic respiratory failure associated with sig-
nificant morbidity and mortality in critically-ill patients.
Although the reported mortality from ARDS has de-
clined in interventional studies over the past decades
[1], observed death rates remain high in observational
studies [2]. Survivors of ARDS experience varying de-
grees of pulmonary, physical, cognitive, emotional and
psychological disability leading to a substantial and sus-
tained disease burden [3]. Since its first description in
1967 [4], several attempts have been made to define a
diagnostic criteria, that reliably identifies a cohort of pa-
tients with the corresponding pathological changes to
aid both the diagnosis and management of ARDS, and in
targeted research. Amongst many, Murray’s lung injury
score (LIS), American European Consensus Conference
(AECC) diagnostic criteria and more recently the Berlin
definition of ARDS are the most commonly adopted def-
initions of ARDS [5-7].
Despite several refinements, current definitions are
still hampered by lack of specificity as demonstrated by
autopsy studies [8,9]. ARDS is arguably a heterogeneous
spectrum of conditions with variable aetiology, response
to treatment and natural progression. Moreover, whilst
evolution in supportive therapy may be contributing to
the apparent improved outcome, lack of effective treat-
ments remains a major on-going challenge. Consequently,
there is a lack of coherent clinical guidance (by any of the
critical care authoritative bodies), that incorporates all of
the care bundles required to manage ARDS. Comparable
guidelines do exist for conditions such as the sepsis syn-
dromes, which incorporate strategies to minimise the de-
velopment of ARDS [10].
This survey was conducted to identify current clinical
practice in relation to diagnostic criteria and treatment
of ARDS, as well as to explore perceptions about the
epidemiology of this condition. Additionally, information
regarding participation in clinical research and the use
of data management resources to identify patients with
ARDS was also explored.
Methods
The survey questionnaire was developed using an online
electronic survey engine (Survey Monkey) by two critical
care physicians and a critical care research fellow (RC,
MPW and AD). This was internally piloted among the
general intensive care physicians at University Hospital
Southampton NHS Foundation Trust. The questionnaire
was subsequently modified and finalised based on the
feedback received. Ethical approval was obtained from
the University of Southampton Ethics and Research
Committee (ERGO Number 1242). A link to the survey
was posted on The Intensive Care Society (ICS), UK,website and advertised on three occasions in the monthly
electronic ICS newsletter. In addition, all intensive care
physicians registered with the ICS were approached indi-
vidually via e-mail to participate. The survey was con-
ducted for a period of three months from October 2012 to
December 2012. No formal consent was required for the
survey participation.
The questionnaire was aimed at intensive care physi-
cians managing adult patients (more than 18 years of
age) with ARDS across all general and specialist units in
the UK. The survey questionnaire explored the following
themes (Additional file 1).
1. Diagnosis: The physician’s preference and use of
existing diagnostic definitions for ARDS.
2. Epidemiology: The physician’s perceptions on the
epidemiology of ARDS within the UK.
3. Management: The ventilation, fluid balance,
pharmacological strategies and rescue measures
adopted in the management of patients with ARDS.
4. Post discharge rehabilitation: The availability of
generic and specialist rehabilitation programmes.
5. Participation in clinical trials
6. Data gathering: The availability of health
informatics to identify patients with ARDS.
Numerical data are presented as percentages of total
respondents to that particular question.
Results
Characteristics of respondents
One hundred and ninety one respondents from 125 hos-
pitals replied to the questionnaire (Figure 1). This was
an 11% response rate from all critical care physicians
registered at The Intensive Care Society, UK. Eighty two
per cent of the respondents were from England, followed
by Scotland (9%), Wales (6%), and Northern Ireland (0.5%).
Three percent were from outside of the UK (Australia,
Canada, Oman and the Channel Islands). Most of the
respondents were physicians managing general intensive
care units (82%) followed by specialist cardiac (8%), neuro-
science (3%) and respiratory units (2%). The remainder
comprised other specialist units including burns, hepato-
biliary, transplant and mixed units. Each unit on average
had 16 beds (range 4–106), accounting for 2.6% of total
hospital beds. Ninety-seven per cent of respondents
were consultants with the remainder consisting of se-
nior trainees (3%). We did not further analyse responses
by seniority of respondent or geographical location.
Diagnostic definitions
All of the respondents answered this question and the
most frequently used definition for ARDS was the AECC
criteria. Thirty per cent used a combination of AECC/
Figure 1 Pictorial representation of the locations of hospitals
from which the responses obtained.
Dushianthan et al. BMC Anesthesiology 2014, 14:87 Page 3 of 8
http://www.biomedcentral.com/1471-2253/14/87LIS/Berlin definition and Delphi Consensus Criteria
[5-7,11], while 15% used no rigid classifications. The Berlin
definition of ARDS and Murray’s LIS was used alone to
identify patients by 12% and 9% respectively (Figure 2).
Although, AECC criteria was the commonest definition
utilised, the use of a pulmonary artery catheter in this
context was not further assessed by the questionnaire.
Epidemiology
Ninety seven and 100% of respondents respectively replied
to the questions regarding the incidence and mortality of
ARDS. Forty five percent felt that the incidence of ARDS0
None of the above
AECC/LIS/Berlin/Delphi Combination
Berlin Definition
LIS
AECC Criteria
Figure 2 Diagnostic definitions utilised to identify patients with ARDS.
Consensus Criteria [6]; LIS, Murray’s Lung Injury Score [5]; Berlin, Berlin defwas declining and 63% felt that mortality was decreasing.
Approximately one third felt that the incidence and
mortality are static in their ARDS population (38% and
30% respectively). Less than 10% felt that incidence
and mortality of ARDS was increasing. Opinions were
evenly spread across the regions regardless of size and
nature of the intensive care units or whether they were
teaching or district general hospital units.
Ventilation strategy
Ninety six percent responded to the question regarding
primary ventilation strategies for ARDS. This question
was primarily based on the ARDSnet protocol [12]. Thirty
four per cent of respondents were fully compliant with
ARDSnet protocol. An additional 51% were partially com-
pliant with deviations in the PEEP recommendations
noted. High frequency oscillatory ventilation (HFOV) was
used by 13% as a primary ventilation strategy. These units
were in-general based in university hospitals (70%). Air-
way pressure release ventilation (APRV), extracorporeal
lung support (ECLS) and extracorporeal CO2 removal de-
vices (ECCO2R) were only used by few respondents (<5%)
as a primary ventilation strategy during the early stages of
ARDS.
Respondents titrated positive end expiratory pressure
(PEEP) according to different parameters. These included:
the degree of hypoxia (74%), the ARDSnet protocol (34%)
and the lower inflection point of the inspiratory pressure-
volume curve (31%). The use of thoracic ultrasound,
oesophageal pressures, end expiratory transpulmonary
pressures and functional imaging such as electrical imped-
ance tomography was rarely used to guide PEEP appliance
(<2%). Computerised tomography (CT) scanning was only
used in 3% of units to assess recruitability and all of these
units were based in university hospitals.
For refractory hypoxemia/hypercapnia in the face of
optimal ventilation, rescue measures included: recruit-
ment manoeuvres (85%), prone positioning (84%), HFOV
(50%), ECLS (33%) and ECCO2R devices (27%).Response (%)
10 20 30 40 50
Expressed as percentage of total responses. AECC, American European
inition of ARDS [7]; Delphi, Delphi Consensus Criteria for ARDS [11].
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Almost all (>99%) provided answers for questions relating
to blood gas targets. Forty two percent of respondents
used no specific set limits for PaCO2 during mechanical
ventilation, but of those who set limits, the majority (49%)
were happy to maintain PaCO2 levels between 7–11 kilo-
pascals (kPa) (Figure 3A). Although the level of permissive
acidaemia varied amongst respondents, 35% aimed to
maintain an arterial pH between 7.21-7.25 (Figure 3B).
Permissive hypoxemia targets were set by the majority
(91%), with 42% aiming for a PaO2 between 8.1-9.0 kPa,
followed by 7.1-8.0 kPa in 36% (Figure 3C).Pharmacological treatments
We have categorised responses to the treatment frequency
with available pharmacological agents as “routine”, “occa-
sional”, “individualised according to patient” and “never”.
For the purpose of this review, we have pooled together
“occasional” and “individualised according to patient”
groups.β2-agonists
Ninety eight percent responded to this question, with
60% stating that they would use β2-agonists in the man-
agement of ARDS. Eleven per cent use β2-agonists rou-
tinely. We point out however, that the exact desired effectFigure 3 Permissive arterial blood gas targets for Pa02 (kPa) (A), pH (of β2-agonists was not clearly defined by the questionnaire
(i.e. bronchodilatation or pulmonary oedema clearance).Corticosteroids
Corticosteroids were used by 70% of the respondents,
with only 6% using them routinely. The preferred cor-
ticosteroid was methylprednisolone (56%), followed by
hydrocortisone (41%). Prednisolone use was scarce (3%).
There was also considerable variation in the dose of corti-
costeroids prescribed (Table 1). Among those respondents
who prescribed corticosteroids (70% of total), eighteen
per cent initiated corticosteroid therapy less than
72 hours after the onset of ARDS, a further 12% within
one week, 38% between 7 and 14 days and 15% after
two weeks. The duration of therapy was ≤1 week in 56%
and between 8–14 days in 34%. Corticosteroids are be-
ing used for their anti-fibrotic properties alone in 42%
and anti-inflammatory effect alone in 23%. The remaining
25% suggested they are using corticosteroids for both clin-
ical effects. The method of corticosteroid cessation was
abrupt in 37% and by a tapered reducing-dose regime in
63%. Free text comments highlighted that the use of corti-
costeroids were dependent on several other factors. These
included: concomitant use of vasopressors (especially in-
creasing doses); the presence of sepsis; radiological (CT)
evidence of ARDS with active lung fibrosis; treatmentB) and PaC02 (C). Presented as percentage of total responses.
Table 1 The type and dose of steroid therapy initiated for acute respiratory distress syndrome
Type of
corticosteroid
Dose (mg/kg/day) Total response (N)
≤1 mg 2 mg 3 mg 4 mg ≥5 mg
Hydrocortisone 23.6 (%) 33.3 (%) 31.4 (%) 7.8 (%) 3.9 (%) 51
Prednisolone 100 (%) 0 (%) 0 (%) 0 (%) 0 (%) 3
Methylprednisolone 42.0 (%) 27.5 (%) 1.5 (%) 5.8 (%) 23.2 (%) 69
The data expressed as a percentage of responses to the total response for the type of corticosteroid initiated.
Response (%)
0 20 40 60 80 100
Physical
Pulmonary
Nutrional
Psychological
Routine
Available
No
Don't know
Figure 4 Availability of specific rehabilitation programmes
following discharge for ARDS patients. Expressed as percentage
of total responses.
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dogenous steroid deficiency.
Neuromuscular blocking agents (NMB)
Eighty three percent of respondents use “occasional” or
“individualised NMB as part of the management of
ARDS. Fifteen per cent of respondents describe using
NMB “routinely”.
Prostaglandins or their derivatives
The majority of respondents (56%) reported never using
prostaglandins or their derivatives in the management of
ARDS, whilst 1.6% reported using them “routinely”. The
remaining responses (42%) were equally divided between
“occasional” and “individualised” use.
Statins
Most had “never” used statins (74%) and few used them
“routinely” (3%). The remainder declared that statin use
was “occasional” or “individualised” according to the pa-
tient (or indeed if part of a clinical research study).
Others
Most commented that they rarely used pulmonary sur-
factants (5%), heliox (7%) or nitric oxide (29%) as part of
their pharmacological treatment strategy for patients
with ARDS. Immunonutrition was used “routinely” by
9% and “occasional/individualised” according to patient
requirement by 24%.
Fluid balance
We asked specific daily fluid balance targets for patients
with ARDS and this was answered by 98%. Thirty two
percent (32%) would aim a negative balance of between
500–1000 millilitres per day (ml day−1), 23% aim for a
negative balance of up to 500 ml day−1, 20% aim a neu-
tral fluid balance and 9% would accept a positive balance
up to 500 ml day−1. Additional comments suggested that
the patient’s cardiovascular status and any evidence of
renal impairment would dictate the target fluid balance.
Tracheostomy
We asked whether tracheostomy is considered in this
patient group routinely, occasionally or rarely, and fur-
ther subdivided these categories into early (before 7 days)or late (after 7 days). This was answered by 98%. Most
would perform a tracheostomy routinely (58%), with
64% stating that a late tracheostomy is the preferred op-
tion. Thirty four percent would perform tracheostomy
occasionally (again the majority after 7 days). Tracheos-
tomy was performed rarely by just 5%.
Follow-up and the availability of rehabilitation
programmes
Forty two percent (42%) follow-up this cohort of pa-
tients routinely after discharge. 98% responded to the
question regarding the availability of any specific re-
habilitation programmes following ICU discharge. Rou-
tine physical and pulmonary rehabilitation was available
at 25% and 10% of respondent’s units respectively. Avail-
ability of routine nutritional and psychological support
was not common (Figure 4).
Participation into clinical research and data collection
Half of the respondents enrol their patients into clinical
research. ARDS disease-specific data collection was per-
formed by 25% and this was available electronically in
about two thirds. Research participation resulted in spe-
cific ARDS data collection in a further 25%. No form of
specific data collection was undertaken in 42% of the re-
spondent’s units.
Discussion
This is the first comprehensive survey describing diagnos-
tic criteria, perceptions about epidemiology and treatment
approaches for the management of ARDS in the UK. Des-
pite significant morbidity and mortality from ARDS, there
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burden and a lack of consistency in management strat-
egies adopted in the UK. Overall, we received 191 re-
sponses from 125 intensive care units of which 121 were
within the UK. It must be highlighted that several major
trials into ARDS were published around the time of this
survey, which may make the responses to some questions
difficult to interpret and the responses we gleaned may
not now be a reflection of current clinical practice [13-15].
Although several diagnostic definitions have evolved
over the years in an attempt to homogenise the hetero-
geneous ARDS population, the utility of these criteria
outside clinical research remains controversial and their
traction limited. Our survey conducted on intensive care
physicians across the UK, indicates that significant varia-
tions remain in the preference as to which of the exist-
ing diagnostic definitions for ARDS is used. Despite the
recent changes, most intensive care physician we sur-
veyed still seem to prefer the AECC diagnostic criteria
to the Berlin definition of ARDS. However, this survey
was conducted shortly after the proposal of Berlin defin-
ition and the less frequent use of this definition com-
pared to AECC criteria, may be as a result of lag time
between publication and clinical implementation. That
being said, 15% used no specific definitions for ARDS
with most of those feeling that these definitions provide
no additional benefit in routine clinical practice. Further-
more, free text comments described how some clinicians
used clinical judgement alone (2%), whilst others felt that
the use of definitions outside trials added no clinical value
as long as lung protective ventilation strategies were
adopted (3%). Indeed this raises a major issue and may
have clinical implications in ARDS patient’s care and trial
recruitment. If a specific target population is not identified
using these definitions, it would be rather difficult to con-
ceive treatment strategies translated from clinical trials or
to test any novel therapy in that particular population.
Regarding the incidence and mortality of ARDS in the
UK, there are no prospective large epidemiological stud-
ies to date. Webster conducted the first documented epi-
demiological study into ARDS across Yorkshire in 1988
(again a survey) [16]. Following this, Abel performed a
single centre observational study between 1990 and 1997
[17]. This single centre study suggested that the mortality
of ARDS had declined over this period from 66% to 44%.
The ALIVE study (epidemiology and outcome of acute
lung injury in European intensive care units) recruited pa-
tients from across Europe, also enrolling patients from the
UK. Among this cohort the hospital mortality of ARDS
was 58% [18]. Among the recent interventional rando-
mised controlled trials into ARDS (BALTI-2 and OSCAR),
the overall mortality was 29% and 41% respectively
[13,19]. This variation in reported mortality is likely to
be due to several reasons including the interventionperformed, inclusion and exclusion criteria, the popula-
tion studied and a variable application of lung protective
ventilation. Respondents to our survey felt that the inci-
dence and mortality in ARDS is decreasing and this is
consistent with clinical trials published by the ARDS
network over the past decade [1]. A large multi-centre,
prospective, observational study, examining the burden
of acute hypoxic respiratory failure is currently complete
and awaiting publication. This may provide additional
morbidity and mortality data, which may complement
the existing literature (LUNG SAFE, NCT02010073).
There were significant variations in the use of pharma-
cological agents for the management of patients with
ARDS, although most of which were in keeping with the
established evidence or the lack thereof. This particularly
applied to the use of pulmonary surfactants, heliox and
nitric oxide. Despite the lack of clinical evidence and
even with the possibility of harm [13,14], about 60% of
respondents use β2-agonists as part of their treatment
strategy, from routinely to individualised according to
each patient. However, the specific reasons for their use
(either for bronchodilatation or alveolar fluid clearance)
and the mode of delivery (nebulised or intravenous) were
not addressed by the questionnaire. It must be highlighted
that the BALTI-2 study investigating the use of intraven-
ous salbutamol in ARDS patients was published closer to
the time of this survey and the perceived use of β2-agonists
in our study may not be a reflection of current clinical
practice [13]. The use of corticosteroids was much more
common (>70%), although variation remains in the type,
dose and duration of corticosteroids given and in the
method of cessation. Most respondents preferred methyl-
prednisolone at a dose of 0.5-1 mg kg−1, with treatment
commencing between 7 and 14 days. Despite the lack of
evidence and even with the possibility of harm, 15% of
respondents still use corticosteroids after 14 days [20].
Protective lung ventilation with low tidal volumes is
the primary ventilation strategy adopted by many since
the publication of the seminal ARDSnet study [12]. How-
ever, it is not always possible to comply with this strategy
of ventilation, as it can be associated with worsening of
gas exchange [21]. Among the respondents, the primary
ventilation strategy is principally based on ARDSnet
protocol, though with frequent deviations to the recom-
mended PEEP, tidal volumes and fraction of inspired
oxygen (Fi02). HFOV is utilised by 13% as a primary
ventilation strategy, and 50% would use it as a rescue
method if there was no improvement (or indeed wors-
ening) in oxygenation/carbon dioxide clearance despite
optimal ventilation. This survey was conducted prior to
the recently published negative outcome studies into
HFOV in ARDS [19,22], so consequently the results
from this survey may not be representative of current
clinical practice.
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ment of patients with ARDS. Studies have suggested that
maintaining a neutral cumulative fluid balance is associ-
ated with an improved patient outcome [23]. Indeed the
extent of a positive fluid balance in critically ill patients
is associated with worsening clinical outcome [24]. In
our survey, most respondents (>50%) preferred a nega-
tive overall cumulative fluid balance for their patients
and this is in keeping with current evidence.
ARDS survivors are left with significant physical, cog-
nitive and psychological sequelae. Little is known about
the availability of routine rehabilitation programmes fol-
lowing discharge from UK hospitals. Only a quarter of
respondents had facilities for routine physical rehabilita-
tion following discharge and there remains a significant
lack in nutritional and psychological support. This survey
highlights the deficiency in specific rehabilitation pro-
grammes for improving patient morbidity following in-
tensive care discharge and prospective epidemiological
studies are needed to assess the precise health, social and
economic implications of this lack in service provision.
The participation of 50% of our responders into ARDS-
specific clinical research is encouraging. The continued
lack of clinical benefit from randomised controlled trials
into ARDS reiterates the importance of on-going research
in this area. In the UK there are no data registries specific
to ARDS, and the Intensive Care National Audit and
Research Centre (ICNARC) case mix programme, which
mainly concentrates on entry diagnosis, does not iden-
tify the majority of patients who develop ARDS during
their intensive care admission. Research into any specific
disease requires an accurate epidemiologic assessment for
resource allocation and trial coordination. This lack of
clarity in the true epidemiology of ARDS, not only for
research purposes but also to recognise the nationwide
impact of this deadly syndrome, is therefore ongoing.
Our survey has several limitations. Only 11% of total
fellows registered on The Intensive Care Society, UK,
responded to the questionnaire, which also included a
small proportion trainees (3% overall). This low response
rate may not be a true representation of the overall UK
practice and highlights the limitation of this data on gen-
eralisability and external validity. Secondly, our method of
electronic approach and participation may have resulted
in some degree of selection bias as recruitment via the
ICS website and e-mail list may have inadvertently se-
lected a particular type of intensive care doctor. Further-
more, the respondents may have had a particular interest
in ARDS management and thus our survey may not be an
overall reflection of the generalised UK practice. This may
possibly explain the high proportion of research participa-
tion among our responders. Thirdly, we cannot rule out
sampling bias due to the nature of the recruitment of
respondents. The sampling time for this survey wascontemporaneous with several major UK randomised
clinical trials into ARDS, that required high levels of en-
gagement from UK-based critical care physicians (OSCAR,
December 2007 - July 2012; BALTI-2, December 2006 -
March 2010; TracMan, November 2004 - January 2011)
[13,19,25]. Indeed, subsequent publication of the results
from these trials makes the responses to some questions
difficult to interpret.
Conclusions
The survey examines the critical care physician’s views
and practices in relation to ARDS management within
the UK between October and December 2012. We have
demonstrated considerable variation in both perceptions
and practices. The use of some supportive therapies with
a strong evidence base such as ventilator strategies are
routinely used. Whereas, diagnostic criteria and pharma-
cotherapies are inconsistently applied. This degree of
variation supports the need for the development of evi-
dence based guidelines in this area.
Key messages
 The majority of clinicians use AECC or Berlin
criteria to define ARDS.
 Most clinicians use ARDSnet guidelines
(at least to some degree) to manage their patients.
 Advanced ventilation techniques are used by less
than half the clinicians.
 There is little standardisation in the use of
pharmacotherapies.
Additional file
Additional file 1: Survey questionnaire.
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